In this study, we preliminarily predicted the compound components and their targets and pathways of YCWLP for the treatment of NASH by network pharmacology and verified the effects of YCWLP on lipid accumulation and inflammation in NASH by in vitro experiments, and the mechanism of its pharmacological efficacy may be related to the inhibition of pyroptosis mediated by the SHP2/PI3K/NLRP3 pathway. The gene discussed is PIK3CA; the disease is metabolic dysfunction-associated steatohepatitis.